Roche plans striking new Basel offices
pharmafile | January 4, 2010 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Basel, Roche, construction
Roche has unveiled plans for its new main office building in Basel, Switzerland, that will accommodate more than 1,800 people from its research, development, production, marketing and corporate functions.
“Roche needs a new office building in Basel”, commented Roche chief executive Severin Schwan. “We are convinced that having all the company’s departments close to each other will be crucial in ensuring that they work together successfully.”
The 41-storey ‘Building 1’ will cost approximately 550 million Swiss francs and will include an auditorium, cafeteria and a number of ‘communication zones’ for employees to use.
“The new building is a harmonious fit with the rest of our site and meets all our requirements in terms of functionality and engineering”, added Matthias Baltisberger, head of Roche’s site in Basel. “The new office building will enable us to offer our employees attractive workplaces and a top-quality infrastructure.”
The new building continues the predominantly white colour scheme that is typical of the Roche site in Basal and has also been adopted for the research and development building currently being built on Basel’s Wettsteinallee.
Both new buildings have been designed by Herzog and de Meuron and tie in with the architectural idiom defined by Otto Salvisberg, Roche said, adding that the new office building continues its longstanding tradition of high-quality industrial architecture.
Subject to gaining planning and development approval work on Building 1 will begin in 2012 and is due to be completed by 2015.
Related Content
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …
Roche advances treatment for Parkinson’s disease
Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, …
